Cargando…

Optimal management of drug-resistant tuberculosis: Can India lead the way?

Detalles Bibliográficos
Autores principales:	Masini, Tiziana, Furin, Jennifer, Udwadia, Zarir, Guglielmetti, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Practice: Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319374/ https://www.ncbi.nlm.nih.gov/pubmed/37202941 http://dx.doi.org/10.4103/ijmr.ijmr_300_23

Ejemplares similares

Quality of drug-resistant tuberculosis care: Gaps and solutions
por: Udwadia, Zarir, et al.
Publicado: (2019)

India should speed up access to bedaquiline-based all-oral regimens, not procrastinate further
por: Udwadia, Zarir F, et al.
Publicado: (2021)

How to protect the protectors: 10 lessons to learn for doctors fighting the COVID-19 coronavirus
por: Udwadia, Zarir F., et al.
Publicado: (2020)

The need to accelerate access to new drugs for multidrug-resistant tuberculosis
por: Cox, Helen S, et al.
Publicado: (2015)

Tuberculosis Management by Private Practitioners in Mumbai, India: Has Anything Changed in Two Decades?
por: Udwadia, Zarir F., et al.
Publicado: (2010)

Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications
por: Husain, Aliabbas A., et al.
Publicado: (2021)

Disseminated tuberculosis with immune thrombocytopenic purpura
por: Dagaonkar, Rucha S., et al.
Publicado: (2012)

Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai
por: Udwadia, Zarir F., et al.
Publicado: (2014)

COVID-19 care in India: the course to self-reliance
por: Balsari, Satchit, et al.
Publicado: (2020)

Tuberculosis in South Asia: a tide in the affairs of men
por: Basnyat, Buddha, et al.
Publicado: (2018)

New treatments for Drug Resistant TB: Past imperfect, future bright
por: Udwadia, Zarir F., et al.
Publicado: (2023)

Can the personalized medicine approach contribute in controlling tuberculosis in general and India in particular?
por: Khan, Nikhat, et al.
Publicado: (2020)

Subnational Burden of Disease Studies: Mexico Leads the Way
por: Tobias, Martin
Publicado: (2008)

Effective use of telemedicine in Mumbai with a cohort of extensively drug-resistant “XDR” tuberculosis patients on bedaquiline during COVID-19 pandemic
por: Udwadia, Zarir F., et al.
Publicado: (2021)

Childhood and Adolescent Anemia Burden in India: The Way Forward
por: Kurpad, Anura Viswanath, et al.
Publicado: (2022)

Can India lead the way in neglected diseases innovation?
por: Thomas, Zakir, et al.
Publicado: (2019)

Is indiscriminate use of medicines the main reason for problems faced during the second wave of COVID-19 in India? – Authors' reply
por: Udwadia, Zarir, et al.
Publicado: (2021)

Nosocomial Tuberculosis in India
por: Pai, Madhukar, et al.
Publicado: (2006)

Impact of Air Pollution on Child Health in India and the Way Forward
por: Dey, Sagnik
Publicado: (2022)

Extensively Drug-Resistant Tuberculosis, Lesotho
por: Satti, Hind, et al.
Publicado: (2008)

Private patient perceptions about a public programme; what do private Indian tuberculosis patients really feel about directly observed treatment?
por: Pinto, Lancelot M, et al.
Publicado: (2010)

Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai
por: Udwadia, Zarir F, et al.
Publicado: (2016)

Ways Health Care Providers Can Promote Better Medication Adherence
por: Bussell, Jennifer K., et al.
Publicado: (2017)

Extensive Drug Resistance in Malaria and Tuberculosis
por: Wongsrichanalai, Chansuda, et al.
Publicado: (2010)

Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India
por: Resendiz-Galvan, Juan Eduardo, et al.
Publicado: (2023)

Contextualising evidence-based recommendations for the second wave of the COVID-19 pandemic in India
por: Balsari, Satchit, et al.
Publicado: (2021)

Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with inhA Mutations
por: Wasserman, Sean, et al.
Publicado: (2020)

Nature can still be the strongest help against aging and neurodegeneration: the sirtuins way
por: Della-Morte, David, et al.
Publicado: (2022)

Can changing the prodrug moiety in remdesivir be a life-saving strategy in COVID-19 infection?
por: Prabha, Praisy K., et al.
Publicado: (2023)

Establishing peer support groups for diabetic retinopathy in India: Lessons learned and way ahead
por: Gudlavalleti, Anirudh Gaurang, et al.
Publicado: (2020)

Preventive Therapy for Contacts of Drug-Resistant Tuberculosis
por: Kherabi, Yousra, et al.
Publicado: (2022)

Isoniazid-resistant tuberculosis: A problem we can no longer ignore
por: Sulis, Giorgia, et al.
Publicado: (2020)

Treatment of drug-resistant tuberculosis
por: Pinto, Lancelot, et al.
Publicado: (2011)

The Reductionist Conundrum of an “Updated” Definition of Extensively Drug-Resistant Tuberculosis
por: Mitnick, Carole D., et al.
Publicado: (2021)

Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres
por: Riccardi, Niccolò, et al.
Publicado: (2019)

Clonal Population of Mycobacterium tuberculosis Strains Reside within Multiple Lung Cavities
por: Vadwai, Viral, et al.
Publicado: (2011)

Sustainability of airlines in India with Covid-19: Challenges ahead and possible way-outs
por: Agrawal, Anshu
Publicado: (2020)

Heteroresistance to rifampicin & isoniazid in clinical samples of patients with presumptive drug-resistant tuberculosis in Central India
por: Desikan, Prabha, et al.
Publicado: (2023)

Improving the estimation of the tuberculosis burden in India
por: Cowling, Krycia, et al.
Publicado: (2014)

What India can learn from globally successful malaria elimination programmes
por: Sharma, Sachin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h6a3dbhbtvodc6858smmm8sstd